Clinical trials: Adult Hepatocellular Carcinoma
HCC, Liver Cirrhosis
SALT for Liver Cirrhosis With HCC
HCC is the third leading cause of cancer deaths worldwide. Although surgical treatment may be effective in patients with HCC, the five-year survival rate is only 50-70%.
- Trial name
- NCT06069947
- Testing
- sequential adult left lateral lobe liver transplantation (SALT)
- Volunteers
- 40 people
- Sponsor
- RenJi Hospital
Hepatocellular Carcinoma (HCC), Liver Ablation
International Study on Treatment of Liver (HCC) Patients With IRE
Procedural data will be recorded from patients with liver lesions from hepatocellular cancer who have been assessed by an appropriately constituted MDT (or equivalent) as appropriate to receive irreversible electroporation
- Conditions
- Hepatocellular Carcinoma (HCC), Liver Ablation, Liver Cancer, Adult
- Trial name
- LIVERHCC-IRE (NCT07192731)
- Testing
- Irreversible Electroporation
- Where
- United Kingdom
- Volunteers
- 50 people
- Sponsor
- Angiodynamics, Inc.
Liver Cancer
Sorafenib Tosylate Before and After Hepatic Arterial Chemoembolization With Doxorubicin Hydrochloride and Mitomycin C in Treating Patients With Localized Liver Cancer That Cannot Be Removed by Surgery
RATIONALE: Sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00949182
- Testing
- sorafenib tosylate, HACE : Doxorubicin Hydrochloride and Mitomycin C, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Rutgers, The State University of New Jersey
Liver Cancer
Panobinostat and Sorafenib in Treating Patients With Liver Cancer That is Metastatic and/or Cannot Be Removed by Surgery
RATIONALE: Panobinostat and sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Sorafenib may also stop the growth of liver cancer by blocking blood flow to the tumor.
- Trial name
- NCT00873002
- Testing
- panobinostat, sorafenib tosylate
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Case Comprehensive Cancer Center
Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer
Sorafenib Tosylate With or Without Stereotactic Body Radiation Therapy in Treating Patients With Liver Cancer
This randomized phase III trial studies sorafenib tosylate and stereotactic body radiation therapy to see how well they work compared to sorafenib tosylate alone in treating patients with liver cancer.
- Conditions
- Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer, Recurrent Adult Primary Liver Cancer
- Trial name
- NCT01730937
- Testing
- Sorafenib, stereotactic body radiation therapy
- Where
- 51 sites in United States, Australia and 3 more
- Volunteers
- 193 people
- Sponsor
- Radiation Therapy Oncology Group
Colorectal Cancer, Islet Cell Tumor
Isolated Hepatic Perfusion With Melphalan in Treating Patients With Primary Unresectable Liver Cancer or Liver Metastases
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving drugs in different ways may kill more tumor cells.
- Conditions
- Colorectal Cancer, Islet Cell Tumor, Liver Cancer, Metastatic Cancer
- Trial name
- NCT00019786
- Testing
- isolated perfusion, melphalan, conventional surgery
- Where
- United States
- Volunteers
- 67 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Liver Cancer
Hepatic Arterial Chemoembolization With Cisplatin or Internal Radiation Therapy in Treating Patients With Advanced Liver Cancer That Cannot Be Removed By Surgery
RATIONALE: Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00109954
- Testing
- cisplatin, brachytherapy, yttrium Y 90 glass microspheres
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- University of Pittsburgh
Breast Cancer, Colorectal Cancer
UMCC 003 Cancer-Related Protein Biomarkers in Blood and Tumor Tissue of Patients With Cancer
RATIONALE: Studying samples of blood and tumor tissue in the laboratory from patients with cancer and blood from healthy participants may help doctors learn more about changes that may occur in DNA and identify biomarkers related…
- Conditions
- Breast Cancer, Colorectal Cancer, Esophageal Cancer, Liver Cancer
- Trial name
- IRB 2000-294 (NCT00900094)
- Testing
- fluorescence in situ hybridization, polymerase chain reaction, protein expression analysis
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- University of Michigan Rogel Cancer Center
Liver Cancer
T900607 in Treating Patients With Unresectable Liver Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of T900607 in treating patients who have unresectable…
- Trial name
- NCT00054262
- Testing
- T900607
- Where
- United States
- Sponsor
- University Hospitals Seidman Cancer Center
Soft Tissue Sarcoma, Renal Cell Carcinoma
A Study of HFB301001 in Adult Patients With Advanced Solid Tumors
The purpose of this study is to test the safety and tolerability of HFB301001 in patients with advanced cancers. There are two parts in this study.
- Conditions
- Soft Tissue Sarcoma, Renal Cell Carcinoma, Uterine Carcinosarcoma, Hepatocellular Carcinoma
- Trial name
- NCT05229601
- Testing
- HFB301001
- Where
- 10 sites in United States, Spain
- Volunteers
- 31 people
- Sponsor
- HiFiBiO Therapeutics
Advanced Hepatocellular Carcinoma
Study of Efficacy and Safety INC280 in Patients With Advanced Hepatocellular Carcinoma
This study is establish whether INC280 is safe and has beneficial effects in patients with advanced hepatocellular carcinoma known to have dysregulation of c-MET pathway and whose disease progressed while on, or after, treatment…
- Trial name
- NCT01964235
- Testing
- INC280
- Where
- 15 sites in United States, Australia and 5 more
- Sponsor
- Novartis Pharmaceuticals
Cancer
Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer
Phase I trial to study the effectiveness of trastuzumab plus R115777 in treating patients who have advanced or metastatic cancer.
- Trial name
- NCT00005842
- Testing
- trastuzumab, tipifarnib
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- National Cancer Institute (NCI)
Adult Hepatocellular Carcinoma, Recurrent Hepatocellular Carcinoma
Oral Thalidomide and Tegafur-uracil to Decrease Hepatocellular Carcinoma Recurrence
This single-centered phase II clinical study is to obtain preliminary information on 1-year recurrence-free survival rate, recurrence-free survival and safety profile of thalidomide in combination with tegafur-uracil in…
- Conditions
- Adult Hepatocellular Carcinoma, Recurrent Hepatocellular Carcinoma, Adverse Reaction to Drug, Vascular Endothelial Growth Factor Overexpression
- Trial name
- NCT02447679
- Testing
- thalidomine, tegafur-uracil
- Where
- Taiwan
- Volunteers
- 40 people
- Sponsor
- Chang Gung Memorial Hospital